Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
07.10.2026 15:21
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.
5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong
07.10.2026 14:15
A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar last quarter.
Can Redwire's Microgravity Pharma Work Create New Revenue Streams?
07.10.2026 13:42
RDW expands microgravity applications into pharmaceutical research, creating potential revenue streams through research and licensing.
AeraHUB 26 NYC Brings the Decision-Centric Enterprise to Life
07.10.2026 13:00
MOUNTAIN VIEW, Calif., October 07, 2026--At AeraHUB 26, Aera Technology’s global decision intelligence event, enterprises share how they’re applying AI to the decisions that run the business.
Bristol Myers Squibb (BMY) Secured A Camzyos Label Expansion, Is It Still Undervalued?
07.10.2026 11:11
Bristol-Myers Squibb (BMY) just secured an expanded FDA approval for Camzyos in symptomatic obstructive hypertrophic cardiomyopathy, including eligible pediatric patients. That fresh label update is the starting point for reassessing the stock. The fresh Camzyos label lands as Bristol-Myers Squibb’s share price has climbed 11.47% year to date to US$59.59, even though the 30-day share price return is down 10.82%. Meanwhile, a 39.37% total shareholder return over the past year signals stronger...
Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA
06.10.2026 04:48
Dollar General, Bristol-Myers Squibb and Equinor ASA have been highlighted in this Screen of The Week article.
CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium
05.10.2026 16:12
CAMBRIDGE, England, October 05, 2026--CN Bio, a leading Organ-on-a-chip (OOC) company de-risking drug discovery and development pipelines by enabling earlier, more confident decision-making, today announced the full scientific programme for the 2026 ‘From Insight to Decision’ e-Symposium. Taking place on the 2nd and 8th of December, the event will feature expert-led sessions offering practical, real-world guidance on OOC use within existing R&D strategies.
BMY or ARGX: Which Is the Better Value Stock Right Now?
05.10.2026 14:40
BMY vs. ARGX: Which Stock Is the Better Value Option?
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt
05.10.2026 13:58
Investing.com -- Shares of Bristol-Myers Squibb Co. (NYSE: BMY) fell 2.5% in premarket trading after Leerink Partners downgraded the pharmaceutical giant from Outperform to Market Perform, citing growing skepticism surrounding key candidates in the company’s drug development pipeline.
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?
05.10.2026 12:40
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Stocks With Broker Rating Upgrades Amid Resilient Equity Markets
05.10.2026 12:21
Dollar General, Bristol-Myers and Equinor stand out after broker rating upgrades, backed by projected earnings growth and resilient U.S. equity markets.
3 Value Stocks We Steer Clear Of
05.10.2026 11:31
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
05.10.2026 11:29
Second-Year Champions in Care Campaign Introduces $1 Million Community Grant Program for Medically Underserved CommunitiesPRINCETON, NJ / ACCESS Newswire / October 5, 2026 / Originally published by Bristol Myers SquibbBristol Myers Squibb (NYSE:BMY) recently announced the expansion of Champions in Care, the company's initiative honoring healthcare professionals (HCPs), first launched in 2025. Now in its second year, the campaign builds on its inaugural effort that celebrated HCPs across therapeu
Cramer’s Stop Trading: Bristol Myers
05.10.2026 10:00
CNBC’s Jim Cramer explains why he is keeping an eye on this pharmaceutical company
Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59
05.10.2026 09:04
Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.
Bristol-Myers Squibb (NYSE:BMY) Dividend Quality: High Yield, Sustainability Concerns
03.10.2026 09:00
BMY passes ChartMill’s Best Dividend Stocks screen with a 4.58% yield, but payout sustainability and falling EPS warrant income-investor caution.
How Has Pfizer's Story Changed?
02.10.2026 10:27
Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale
01.10.2026 19:15
Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
01.10.2026 10:59
PRINCETON, N.J., October 01, 2026--Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric
30.09.2026 15:45
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff on its biggest cash generator puts that streak on a collision course with reality in 2027.